Technology / Publications
Several peer reviewed publications validate ARCEDI’s technology
How does cell‐based non‐invasive prenatal test (NIPT) perform against chorionic villus sampling and cell‐free NIPT in detecting trisomies and copy number variations? A clinical study from Denmark
Abstract Objectives: We aimed to compare cell‐based NIPT (cbNIPT) to chorionic villus sampling (CVS) and to examine the test characteristics of cbNIPT in the first
Diagnosis of hydatidiform moles using circulating gestational trophoblasts isolated from maternal blood
Introduction: Identifying hydatidiform moles (HMs) is crucial due to the risk of gestationaltrophoblastic neoplasia. When a HM is suspected on clinical findings, surgical termination isrecommended.
Noninvasive prenatal screening for cystic fibrosis using circulating trophoblasts: Detection of the 50 most common disease‐causing variants
Objectives: Cystic fibrosis (CF) is one of the most common severe autosomal recessive disorders. Prenatal or preconception CF screening is offered in some countries. A
Cell-Based NIPT Detects 47,XXY Genotype in a Twin Pregnancy
Background: The existing risk of procedure-related miscarriage following invasive sampling for prenatal diagnosis is higher for twin pregnancies and some women are reluctant to test
Screening for Fetal Aneuploidy and Sex Chromosomal Anomalies in a Pregnant Woman With Mosaicism for Turner Syndrome—Applications and Advantages of Cell-Based NIPT
Background: Cell-free NIPT and cell-based NIPT are risk-free testing options using maternal blood samples to screen for fetal aneuploidies, but the methods differ. For cell-free
Cell-based non-invasive prenatal testing for monogenic disorders: confirmation of unaffected fetuses following preimplantation genetic testing
Purpose: Proof of concept of the use of cell-based non-invasive prenatal testing (cbNIPT) as an alternative to chorionic villus sampling (CVS) following preimplantation genetic testing
Hydatidiform mole diagnostics using circulating gestational trophoblasts isolated from maternal blood
Background: In gestational trophoblastic disease, the prognosis is related to the genetic constitution. In some cases, taking a biopsy is contraindicated. Methods: In a pregnant
Cell-based non-invasive prenatal diagnosis in a pregnancy at risk of cystic fibrosis
Objective: We aimed to develop cell-based NIPT for cystic fibrosis (CF) and test a pregnancy at risk of two common pathogenic variants. Method: A pregnant
Cell-based noninvasive prenatal testing (cbNIPT) detects pathogenic copy number variations
In two cases, cell-based noninvasive prenatal testing (cb- NIPT) detected copy number variations (CNVs): a 7 Mb de- letion of 15q11q13 covering the Prader-Willi region
The Number of Circulating Fetal Extravillous Trophoblasts Varies from Gestational Week 6 to 20
Cell-based non-invasive prenatal testing (cbNIPT) based on circulating fetal extravillous trophoblasts (fEVTs) has shown to be possible in gestational week (GW) 10–13. Prenatal testing is
Commentary on a combined approach to the problem of developing biomarkers for the prediction of spontaneous preterm labor that leads to preterm birth
Introduction: Globally, preterm birth has replaced congenital malformation as the major cause of perinatal mortality and morbidity. The reduced rate of congenital malformation was not
Do fetal extravillous trophoblasts circulate in maternal blood postpartum?
Introduction: Circulating fetal extravillous trophoblasts may offer a superior alternative to cell-free fetal DNA for noninvasive prenatal testing. Cells of fetal origin are a pure
Does Maternal Body Mass Index Affect the Quantity of Circulating Fetal Cells Available to Use for Cell-Based Noninvasive Prenatal Test in High-Risk Pregnancies?
We present the first study that investigates the effect of ma- ternal body mass index (BMI) on the quantity of circulating fetal cells available to
On the road to replacing invasive testing with cell‐based NIPT: Five clinical cases with aneuploidies, microduplication, unbalanced structural rearrangement, or mosaicism
Objective: Trophoblastic fetal cells harvested from maternal blood have the capacity to be used for copy number analyses in a cell‐based non‐invasive prenatal test (cbNIPT).
Fetal cells in maternal blood for prenatal diagnosis: a love story rekindled
For decades it has been common knowledge that some cells from the developing fetus make their way into maternal circulation, and that this process starts
Genome-wide copy number analysis on DNA from fetal cells isolated from the blood of pregnant women
Objective Non-invasive prenatal testing (NIPT) based on fetal cells in maternal blood has the advantage over NIPT based on circulating cell-free fetal DNA in that
The Number of Endovascular Trophoblasts in Maternal Blood Increases Overnight and after Physical Activity: An Experimental Study
Introduction: Fetal cells in maternal blood may be used for noninvasive prenatal diagnostics, although their low num- ber is a challenge. This study’s objectives were
Fetal Gender and Several Cytokines Are Associated with the Number of Fetal Cells in Maternal Blood – An Observational Study
Screening for fetal chromosome aneuploidies in high risk pregnancies has for decades been offered in many countries. Until now the sampling of fetal material for
A new marker set that identifies fetal cells in maternal circulation with high specificity
Objective Fetal cells from the maternal circulation (FCMBs) have the potential to replace cells from amniotic fluid or chorionic villi in a diagnosis of common
Characterization of Fetal Cells from the Maternal Circulation by Microarray Gene Expression Analysis – Could the Extravillous Trophoblasts Be a Target for Future Cell-Based Non-Invasive Prenatal Diagnosis?
Introduction: Circulating fetal cells in maternal blood pro- vide a tool for risk-free, non-invasive prenatal diagnosis. However, fetal cells in the maternal circulation are scarce,
Subscribe to our newsletter to get the latest updates on products and new scientific publications on ARCEDI technology.